Huntleigh Advisors Inc. Acquires Shares of 117,407 InspireMD, Inc. (NYSE:NSPR)

Huntleigh Advisors Inc. acquired a new position in shares of InspireMD, Inc. (NYSE:NSPR - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 117,407 shares of the company's stock, valued at approximately $316,000. Huntleigh Advisors Inc. owned 0.38% of InspireMD as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Uniting Wealth Partners LLC bought a new position in shares of InspireMD during the 1st quarter worth about $27,000. Renaissance Technologies LLC bought a new position in shares of InspireMD during the 4th quarter worth about $27,000. Schonfeld Strategic Advisors LLC increased its position in shares of InspireMD by 153.2% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company's stock worth $79,000 after purchasing an additional 18,233 shares in the last quarter. Courier Capital LLC bought a new position in InspireMD during the 1st quarter valued at about $81,000. Finally, Northern Trust Corp lifted its holdings in InspireMD by 103.7% during the 4th quarter. Northern Trust Corp now owns 48,022 shares of the company's stock valued at $126,000 after purchasing an additional 24,452 shares during the last quarter. 44.78% of the stock is owned by institutional investors.

InspireMD Trading Up 1.8%

NSPR stock traded up $0.04 during trading on Tuesday, hitting $2.26. 44,033 shares of the stock traded hands, compared to its average volume of 67,508. InspireMD, Inc. has a one year low of $1.99 and a one year high of $3.80. The stock has a market cap of $69.24 million, a price-to-earnings ratio of -3.01 and a beta of 0.57. The company has a 50 day simple moving average of $2.43 and a 200 day simple moving average of $2.65.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on NSPR. Wall Street Zen began coverage on shares of InspireMD in a report on Monday, May 5th. They set a "sell" rating for the company. Piper Sandler cut their price target on shares of InspireMD from $4.50 to $4.00 and set an "overweight" rating for the company in a report on Monday, May 12th.

InspireMD Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.